2017 American Transplant Congress
Outcome of Living-Donor Kidney Transplantation in Cross-Match-Positive Recipients at a Single Center.
BackgroundLiving-donor kidney transplantation in cross-match (XM)-positive patients remains high-risk and requires an optimal desensitization protocol. We started a desensitization protocol for XM-positive patients in January…2017 American Transplant Congress
Does HLA Class of Complement Activating Donor Specific Antibodies Matter: Single Centre Retrospective Analysis of Renal Allograft Outcomes.
Introduction. Complement activating donor specific antibodies may be associated with worse outcomes in a cohort of patients who have undergone HLA-AIT. We looked for differences…2017 American Transplant Congress
Impact of Serum EDTA Treatment on Identification of Unacceptable Antigens for Kidney Transplant Candidates.
Pathology, University of Chicago Medicine, Chicago, IL
BACKGROUND AND AIMS: The prozone effect is one factor causing false negative reactions in HLA antibody testing. EDTA, which is commonly used to remove this…2017 American Transplant Congress
Effective Targeting Plasma Cells with Daratumumab (Anti-CD38) and Mozobil (Anti-CXCR4) in a Sensitized Non-Human Primate Model.
1Surgery, Duke Transplant Center, Durham, NC; 2Surgery, Samsung Medical Center, Seoul, Korea
[Introduction] The presence of donor-specific antibodies (DSA) leads to antibody-mediated rejection (AMR) and decreased graft survival. Therefore efforts continue to be made to reduce DSA…2017 American Transplant Congress
A Novel 3-Dimensional Culture System Enables In Vitro Study of Human Bone Marrow Plasma Cells.
Purpose: Historically, in vitro study of human plasma cells (PCs) has been greatly limited by their short survival (48-72 hrs). Therefore, systems that maintain viability…2017 American Transplant Congress
Pre-Transplant Evaluation of KSORTSM to Assess Risk for Rejection in Highly Sensitized Patients.
Study purpose: To investigate the kSORTSM molecular expression assay for immune risk assessment in renal transplant (tx) recipients prior to tx for correlation of pre-tx…2017 American Transplant Congress
Desensitization versus Deceased Donor Kidney Transplantation: What to Choose When Both Become Available?
1UCSF, San Francisco; 2Johns Hopkins, Baltimore; 3NYU, New York
Kidney allocation system changes have improved deceased donor kidney transplant (DDKT) access for highly sensitized patients. For patients with a willing live donor but requiring…2017 American Transplant Congress
Extended Experience with Tocilizumab (Anti-IL6R) for Difficult to Desensitize (Des) Patients Awaiting HLA Incompatible Kidney Transplant.
Kidney Transplant, Cedars-Sinai Medical Center, LA, CA
INTRODUCTION: ~30% of HS patients fail to respond to DES with IVIG+rituximab. IL6/IL-6R signaling is critical for B-cell differentiation to plasmablasts and IgG production. Tocilizumab…2017 American Transplant Congress
Clinical Outcomes of ABO and HLA Incompatible Kidney Transplantation – Nationwide Cohort Study.
Background This is a nationwide cohort study to investigate the impact of anti-A/B antibody or donor specific anti-HLA antibody (HLA-DSA) on the clinical outcomes in…2016 American Transplant Congress
Virtual Crossmatching Under the New KAS: Safely Bypassing a Physical Crossmatch When Allocating Kidneys to Highly Sensitized Candidates.
1Pathology, Emory University, Atlanta, GA; 2Emory Transplant Center, Emory University, Atlanta, GA.
AIM: On 12/4/2014, the OPTN implemented a new KAS for deceased donor(DD) transplants which, among many changes, increased priority for highly sensitized (HS) candidates (cPRA>98%).…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 15
- Next Page »